Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Metastatic Castration-Resistant Prostate Cancer
NCT00385580Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2007
- Primary completion
- Dec 2008
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of dasatinib in prostate cancer (PCa) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Number of Participants With a Response. Started Jan 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00385580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00385580.